Real-world Evidence

4: ‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC)

12: Efficacy of frontline combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)

13: Complete Responses with first line (1L) antiangiogenic monotherapy in Spanish patients with metastatic renal cell carcinoma (mRCC). The ATILA study

14: Real-World Clinical Outcomes of tivozanib as first-line treatment of metastatic renal cell carcinoma in Germany

15: Image-guided robotic radiosurgery for the treatment of metastases of renal cell carcinoma.

16: Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT

17: Real-world clinical characteristics and treatment patterns in patients with advanced renal cell carcinoma treated with first-line immunotherapy + axitinib in Germany